Hadasit Medical Research Services and Development Ltd.

Galit Eisenberg

Michal Lotem

Arthur Machlenkin

Shoshana Frankenburg

Abraham Rutenberg

Inna Ben David

Tamar Peretz-Yablonsky

Ronny Uzana

Anna Kuznetz

Yael Gelfand

Roni Engelstein

Merav Darash Yahana

Tamar Peretz

The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

Methods for cancer therapy using isolated NTB-A ectodomain polypeptides

Provided is directed to the field of immunotherapy. Specifically, provided are compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the subject matter are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.

Cell compositions and methods for cancer therapy

The present invention relates to cancer immunotherapy, specifically to allogeneic tumor cell vaccines. According to some embodiments, the invention provides novel cell lines useful as therapeutic cell vaccine compositions. The invention further provides advantageous screening methods and means for identifying patients amenable for treatment with partially Human Leukocyte Antigen (HLA) matched allogeneic cell vaccines. Therapeutic compositions and methods for use in proliferative disorders are further provided.

Allogeneic tumor cell vaccination

Growing community of inventors

Modiin, Israel

Galit Eisenberg